Protei

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

C-reactive protein (CRP) is an acute-phase protein that has long been recognized as a marker of systemic inflammation. CRP measurement can complement a range of diagnostic markers to monitor infection and direct treatment. However, as economic rationalization...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, today announcedsignificant progress in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietaryPRS-060 Anticalin(R) candidate, the Company reports that theprotei...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., aprivately-held biopharmaceutical company focused on the developmentof therapeutics to treat metabolic diseases, today announced thepresentation of top line data of its phase 2a study of DIO-902, afir...

Apollo's human proteins boost stem cell research

SYDNEY, Australia, June 21, 2007-At a time when Australianscientists are fighting hard to keep pace with overseas researchand development, an Australian biotech company is leading the worldin the production of human proteins for stem cell research. Apollo CEO John Priest said the company's human proteins areunique in the way they help stem cells to develop into specificcell types s...

New Research Results Show That Investigational Drug Phenoxodiol Targets Cancer Protein, Causing Cancer Cell Death

Worldwide pivotal phase III study in women with recurrent ovariancancer underway SYDNEY, Australia and WASHINGTON, May 01, 2007/PRNewswire-FirstCall/ -- A new study further supports the uniquemechanism of action of phenoxodiol, an investigational drug beingstudied for the treatment of ovarian cancer. The drug appears towork by targeting a certain tumor-specific protein, which triggersa s...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51

Other Presentations at AACR Highlight Progress in SuperGen'sOncology-Focused Pre-Clinical Pipeline LOS ANGELES, April 19, 2007 /PRNewswire-FirstCall/ -- SuperGenInc. today announced that MP470, its multi-targeted tyrosine kinaseinhibitor, suppresses the Rad51 protein, a critical component ofdouble- stranded DNA repair in cancer cells as part of a series ofpresentations at the 2007 America...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

- New Studies Confirm That Fusion Proteins Made by CombiningCytokines With Peregrine's Anti-PS Antibodies Demonstrate IncreasedAnti-Tumor Activity With No Observable Toxicity - LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of canc...

Protein Found to Shield Pancreatic Cancer Cells from Self-Destruction

HOUSTON, March 20, 2007 - An overexpressed proteinprotects human pancreatic cancer cells from being forced to devourthemselves, removing one of the body's natural defenses againstout-of-control cell growth, researchers at The University of TexasM. D. Anderson Cancer Center report in the March issue of MolecularCancer Research. The protein tissue transglutaminase, known by the abbr...

Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences,Inc., a specialty dermatology company, today announced thepublication of a paper in the March 9, 2007 issue of the journalCell by its co-founder and board member, David E. Fisher, M.D.,Ph.D., that identifies two new functions for an important protein,p53, in the pigmentation of skin. Fisher's study shows that inaddition to i...